Sjögren's disease & overlap diseases
Treatment‐Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) and Sjögren's Tool for Assessing Response (STAR) Response to B Cell Therapy in Sjögren's Disease
Authors' conclusion
The distinct ESSDAI and STAR ligand-receptor signatures indicate different systemic biologic drivers of nonresponse to B cell therapies in SjD.
Study context
- Population
- Adults with active Sjögren's disease (SjD) treated with anti-CD20 or BAFF inhibition
- Participants
- 43 adults
- Comparison
- Rituximab (RTX), belimumab (BEL) and sequential BEL-RTX vs placebo; ESSDAI and STAR responders vs nonresponders
Methodological detailswhole blood transcriptomic study, placebo-controlled, whole blood RNA sequencing at baseline and Week 24, ligand-receptor and pathway enrichment analyses
- Whole blood transcriptomic study
- Placebo-controlled
- Whole blood RNA sequencing at baseline and Week 24
- Ligand-receptor and pathway enrichment analyses
Primary result
As reported in the abstract
Week 24
ESSDAI nonresponse: higher baseline TGFβ-2, C4A, CD8A and lower C4BPA expression (AUC)
0.89
STAR nonresponders: higher baseline SPP1, TLR4, IL1R1, IL18R1, IL1RAP, TREM1, FCGR2A expression, IL-1/IL-18/FcγR myeloid module (AUC)
0.80
Original publication
Treatment‐Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease. Arthritis Rheumatol. Published 24 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →